Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1600 1612 1624 3791
This examiner grants 63% of resolved cases
Examiner SHOMER, ISAAC is assigned to Tech Center 3700 and Art Unit 1600. The examiner has a record of 1194 resolved cases. The allowance rate for these applications is 63.2 percent. This rate provides an indication of the likelihood of obtaining a patent grant. The median time to allowance is 1062 days, which establishes the timeframe for successful prosecution. This 1062-day period is a central data point for applicants in this unit.
The interview lift for this examiner is 30.3 percent. This figure shows that conducting an interview is associated with a higher probability of allowance compared to the 63.2 percent baseline. The 30.3 percent lift suggests that direct engagement with the examiner is a method for resolving issues in the 1194 cases handled. Practitioners in Art Unit 1600 can rely on the 1062-day median and the 30.3 percent lift to guide their decisions on whether to request an interview during prosecution in Tech Center 3700.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18649744 | SHEAR-THINNING COMPOSITIONS FOR ABLATION | Final Rejection | Boston Scientific Scimed, Inc. |
| 18760166 | Oral Care Compositions For Active Agent Delivery | Non-Final OA | The Procter & Gamble Company |
| 18040745 | METHODS OF PREPARING LIPID NANOPARTICLES | Final Rejection | ModernaTX, Inc. |
| 18629296 | VACCINE ADJUVANTS, TRANSFECTION REAGENTS, AND METHODS OF USING THE SAME | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18699670 | Microencapsulation | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18290135 | MOLECULAR PROBES FOR IN VIVO DETECTION OF ALDEHYDES | Non-Final OA | The General Hospital Corporation |
| 18273922 | METHODS AND COMPOSITIONS FOR INCREASING THE CONCENTRATION OF CELL FREE DNA | Final Rejection | The General Hospital Corporation |
| 18702663 | HYDROGEL INCLUDING PHENOL DERIVATIVE-MODIFIED CELLULOSE AND USE THEREOF | Final Rejection | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 18287009 | Synthesis of Antimicrobial PVP-coated Bismuth Nanoparticles | Non-Final OA | Board of Regents, The University of Texas System |
| 18549645 | DRY POWDER FORMULATIONS OF NUCLEIC ACID LIPID NANOPARTICLES | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18570450 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE POLAR OIL, A POLYOL AND AT LEAST ONE HYDROPHILIC ACTIVE AGENT | Final Rejection | L'OREAL |
| 18570611 | SUB-MICRON PARTICLE | Final Rejection | IMPERIAL COLLEGE INNOVATIONS LIMITED |
| 18006138 | LAYER-BY-LAYER COATED NANOLIPOSOME FOR ORAL DELIVERY OF INSULIN | Final Rejection | NANYANG TECHNOLOGICAL UNIVERSITY |
| 19018165 | ALPHA POLYGLUTAMATED LOMETREXOL AND USES THEREOF | Non-Final OA | L.E.A.F. HOLDINGS GROUP LLC |
| 18968387 | GAMMA POLYGLUTAMATED RALTITREXED AND USES THEREOF | Non-Final OA | L.E.A.F. HOLDINGS GROUP LLC |
| 17615637 | Compositions of Dicarboxylic Acid Derivatives | Final Rejection | UPL LTD |
| 19009327 | ANTIBODY FORMULATIONS | Non-Final OA | MORPHOSYS AG |
| 17298156 | ANTIBODY FORMULATIONS | Final Rejection | MORPHOSYS AG |
| 18684335 | BROAD SPECTRUM ANTI-MICROBIAL POLYMERIC COMPOSITION | Non-Final OA | CORNELL UNIVERSITY |
| 18144382 | IN VIVO IMMUNOIMAGING OF INTERFERON-GAMMA | Final Rejection | Wayne State University |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy